|
US5538983A
(en)
|
1990-05-16 |
1996-07-23 |
The Rockefeller University |
Method of treating amyloidosis by modulation of calcium
|
|
EP0597956A1
(en)
|
1991-07-29 |
1994-05-25 |
Warner-Lambert Company |
Quinazoline derivatives as acetylcholinesterase inhibitors
|
|
IT1255179B
(it)
|
1992-06-26 |
1995-10-20 |
Enzo Cereda |
Azaciclo e azabiciclo alchiliden idrossilamine
|
|
US5744476A
(en)
|
1994-06-27 |
1998-04-28 |
Interneuron Pharmaceuticals, Inc. |
Dopamine D1 agonists for the treatment of dementia
|
|
JP2992677B2
(ja)
|
1995-06-05 |
1999-12-20 |
武田薬品工業株式会社 |
骨形成促進医薬組成物
|
|
WO1998030243A1
(en)
|
1997-01-08 |
1998-07-16 |
Warner-Lambert Company |
Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
|
|
AU2231199A
(en)
|
1998-01-16 |
1999-08-02 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Alkenyldiarylmethane non-nucleoside hiv-1 reverse transcriptase inhibitors
|
|
YU47600A
(sh)
|
1998-01-27 |
2002-09-19 |
Aventis Pharmaceuticals Products Inc. |
SUPSTITUISANI OKSOAZAHETEROCIKLIL INHIBITORI FAKTORA Xa
|
|
JP2003529531A
(ja)
|
1998-11-25 |
2003-10-07 |
アヴェンティス ファーマシューティカルズ インコーポレイテッド |
置換オキソアザへテロシクリルＸａ因子阻害剤
|
|
KR20020087041A
(ko)
|
1999-07-28 |
2002-11-21 |
아벤티스 파마슈티칼스 프로덕츠 인크. |
치환된 옥소아자헤테로사이클릴 화합물
|
|
JP2001131173A
(ja)
|
1999-08-23 |
2001-05-15 |
Kyorin Pharmaceut Co Ltd |
二環式複素環誘導体
|
|
JP2005231995A
(ja)
|
1999-12-22 |
2005-09-02 |
Meiji Seika Kaisha Ltd |
オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物
|
|
US7084126B1
(en)
|
2000-05-01 |
2006-08-01 |
Healthpartners Research Foundation |
Methods and compositions for enhancing cellular function through protection of tissue components
|
|
WO2002003684A2
(en)
|
2000-06-30 |
2002-01-10 |
Eli Lilly And Company |
Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
|
|
JP2004532200A
(ja)
|
2001-03-15 |
2004-10-21 |
サエジス ファーマシューティカルズ， インコーポレイテッド |
全身性ストレスの後に認識機能を回復するための方法
|
|
US20040023951A1
(en)
|
2001-06-18 |
2004-02-05 |
Bymaster Franklin Porter |
Combination therapy for treatment of psychoses
|
|
US20030004913A1
(en)
|
2001-07-02 |
2003-01-02 |
Koninklijke Philips Electronics N.V. |
Vision-based method and apparatus for detecting an event requiring assistance or documentation
|
|
WO2003045315A2
(en)
|
2001-11-26 |
2003-06-05 |
Cortex Pharmaceuticals, Inc. |
Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
|
|
US20040044023A1
(en)
|
2002-08-30 |
2004-03-04 |
Marc Cantillon |
Compositions and methods for treating or preventing memory impairment
|
|
WO2004073639A2
(en)
|
2003-02-19 |
2004-09-02 |
Merck & Co. Inc. |
Treatment of psychosis with a muscarinic m1 receptor ectopic activator
|
|
CN1777425A
(zh)
|
2003-03-28 |
2006-05-24 |
阿卡蒂亚药品公司 |
用于疼痛控制的毒蕈碱性m1受体激动剂
|
|
US20040266659A1
(en)
|
2003-06-27 |
2004-12-30 |
Stephen LaBerge |
Substances that enhance recall and lucidity during dreaming
|
|
GB0504019D0
(en)
|
2005-02-26 |
2005-04-06 |
Astrazeneca Ab |
Amide derivatives
|
|
US20090156581A1
(en)
|
2005-04-15 |
2009-06-18 |
Board Of Trustrees Of Michigan State University |
Aminergic pharmaceutical compositions and methods
|
|
GB0516570D0
(en)
|
2005-08-12 |
2005-09-21 |
Astrazeneca Ab |
Amide derivatives
|
|
US20110319386A1
(en)
|
2005-08-26 |
2011-12-29 |
Braincells Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
EP2275096A3
(en)
|
2005-08-26 |
2011-07-13 |
Braincells, Inc. |
Neurogenesis via modulation of the muscarinic receptors
|
|
WO2007044937A2
(en)
|
2005-10-13 |
2007-04-19 |
President And Fellows Of Harvard College |
Compositions and methods to modulate memory
|
|
RS55630B1
(sr)
|
2005-12-21 |
2017-06-30 |
Janssen Pharmaceutica Nv |
Triazolopiridazini kao modulatori tirozin kinaze
|
|
GB0607946D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res The Ltd |
Mono and combination therapy
|
|
GB0607949D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res The Ltd |
Mono and combination therapy
|
|
GB0607952D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res Ltd |
Novel treatment
|
|
US8198448B2
(en)
|
2006-07-14 |
2012-06-12 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
PE20121506A1
(es)
|
2006-07-14 |
2012-11-26 |
Amgen Inc |
Compuestos triazolopiridinas como inhibidores de c-met
|
|
US7834023B2
(en)
|
2006-09-20 |
2010-11-16 |
Portola Pharmaceuticals, Inc. |
Substituted dihydroquinazolines as platelet ADP receptor inhibitors
|
|
ZA200904826B
(en)
*
|
2007-01-03 |
2010-09-29 |
Cortex Pharma Inc |
3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
|
|
US8618074B2
(en)
|
2007-03-15 |
2013-12-31 |
Board Of Regents Of The University Of Texas System |
GPCR enhanced neuroprotection to treat brain injury
|
|
EP2195317B1
(en)
|
2007-08-29 |
2012-01-18 |
Schering Corporation |
2,3-substituted azaindole derivatives for treating viral infections
|
|
RU2010111550A
(ru)
|
2007-08-29 |
2011-10-10 |
Шеринг Корпорейшн (US) |
2,3-замещенные индольные производные для лечения вирусных инфекций
|
|
WO2009032124A1
(en)
|
2007-08-29 |
2009-03-12 |
Schering Corporation |
Substituted indole derivatives and methods of use thereof
|
|
NO2200610T3
(enExample)
|
2007-09-21 |
2018-06-09 |
|
|
|
WO2009039461A2
(en)
|
2007-09-21 |
2009-03-26 |
Acadia Pharmaceuticals, Inc. |
N-substituted piperidine derivatives as serotonin receptor agents
|
|
US8765757B2
(en)
|
2007-11-16 |
2014-07-01 |
Merck Sharp & Dohme Corp. |
3-heterocyclic substituted indole derivatives and methods of use thereof
|
|
CN102317285A
(zh)
|
2007-11-16 |
2012-01-11 |
先灵公司 |
3-氨基磺酰基取代的吲哚衍生物及其使用方法
|
|
US20110024198A1
(en)
|
2008-02-19 |
2011-02-03 |
Baker Hughes Incorporated |
Bearing systems containing diamond enhanced materials and downhole applications for same
|
|
WO2010042603A1
(en)
|
2008-10-08 |
2010-04-15 |
Cingulate Neuro Therapeutics, Llc |
Amyloid and depression
|
|
US8557832B2
(en)
|
2008-11-20 |
2013-10-15 |
Merck Sharp & Dohme Corp. |
Aryl methyl benzoquinazolinine M1 receptor positive allosteric modulators
|
|
JP2012518640A
(ja)
|
2009-02-23 |
2012-08-16 |
メルク・シャープ・エンド・ドーム・コーポレイション |
ピラゾロ［４，３−ｃ］シンノリン−３−オンＭ１受容体陽性アロステリックモジュレーター
|
|
WO2010102218A1
(en)
|
2009-03-05 |
2010-09-10 |
Mithridion, Inc. |
Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
|
|
EP2421366B1
(en)
|
2009-04-20 |
2013-08-28 |
Merck Sharp & Dohme Corp. |
Heterocyclic fused cinnoline m1 receptor positive allosteric modulators
|
|
ES2353093B1
(es)
|
2009-05-20 |
2012-01-03 |
Consejo Superior De Investigaciones Científicas (Csic) |
Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas.
|
|
US10265311B2
(en)
|
2009-07-22 |
2019-04-23 |
PureTech Health LLC |
Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
|
|
ES2742728T3
(es)
|
2009-07-22 |
2020-02-17 |
PureTech Health LLC |
Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico
|
|
CN102480964B
(zh)
|
2009-08-31 |
2015-07-08 |
默沙东公司 |
吡喃基芳基甲基苯并喹唑啉酮m1受体正向别构调节剂
|
|
US8895580B2
(en)
|
2009-10-21 |
2014-11-25 |
Merck Sharp & Dohme Corp. |
Quinolinone-pyrazolone M1 receptor positive allosteric modulators
|
|
WO2011075371A1
(en)
|
2009-12-14 |
2011-06-23 |
Merck Sharp & Dohme Corp. |
Pyridoquinazolinone m1 receptor positive allosteric modulators
|
|
WO2011084371A1
(en)
|
2009-12-21 |
2011-07-14 |
Merck Sharp & Dohme Corp. |
Aminobenzoquinazolinone m1 receptor positive allosteric modulators
|
|
US8557992B2
(en)
|
2010-06-15 |
2013-10-15 |
Merck Sharp & Dohme Corp. |
Heterocyclic fused phenanthrolinone M1 receptor positive allosteric modulators
|
|
EP2588104B1
(en)
|
2010-07-01 |
2014-12-10 |
Merck Sharp & Dohme Corp. |
Isoindolone m1 receptor positive allosteric modulators
|
|
WO2012047702A1
(en)
*
|
2010-10-04 |
2012-04-12 |
Merck Sharp & Dohme Corp. |
Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators
|
|
US9549928B2
(en)
|
2011-04-29 |
2017-01-24 |
The University Of Toledo |
Muscarinic agonists as enhancers of cognitive flexibility
|
|
US9284312B2
(en)
*
|
2011-05-17 |
2016-03-15 |
Merck Sharp & Dohme Corp. |
N-methyl tetrahydroquinoline M1 receptor positive allosteric modulators
|
|
WO2012170599A1
(en)
|
2011-06-10 |
2012-12-13 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
US9403802B2
(en)
|
2012-03-02 |
2016-08-02 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and use therefor
|
|
EP2828247B1
(en)
|
2012-03-23 |
2019-01-16 |
PTC Therapeutics, Inc. |
4h-chromen-4-one derivatives for treating spinal muscular atrophy
|
|
US20130289019A1
(en)
|
2012-04-26 |
2013-10-31 |
Amazing Grace, Inc. |
Methods of treating behaviorial and/or mental disorders
|
|
WO2014077401A1
(ja)
|
2012-11-19 |
2014-05-22 |
武田薬品工業株式会社 |
含窒素複素環化合物
|
|
JP6075408B2
(ja)
|
2012-11-22 |
2017-02-08 |
株式会社デンソー |
物標検出装置
|
|
EP2938600B1
(en)
|
2012-12-27 |
2017-01-25 |
F. Hoffmann-La Roche AG |
Comt inhibitors
|
|
CN104955826B
(zh)
|
2013-02-04 |
2019-05-31 |
默克专利股份公司 |
可用于治疗神经学疾病和病症的螺-喹唑酮衍生物
|
|
US10738024B2
(en)
|
2013-05-06 |
2020-08-11 |
Indiana University Research And Technology Corporation |
Compounds for treatment of angiogenesis-mediated diseases
|
|
JP6063400B2
(ja)
|
2014-01-08 |
2017-01-18 |
株式会社日立ビルシステム |
エレベータの異常監視装置
|
|
ES2811088T3
(es)
|
2014-04-23 |
2021-03-10 |
Takeda Pharmaceuticals Co |
Derivados de isoindolin-1-ona como actividad del modulador alostérico positivo del receptor M1 muscarínico colinérgico para el tratamiento de la enfermedad de Alzheimer
|
|
JP6531093B2
(ja)
|
2014-05-16 |
2019-06-12 |
武田薬品工業株式会社 |
含窒素複素環化合物
|
|
EP3156397B1
(en)
|
2014-06-13 |
2019-08-07 |
Takeda Pharmaceutical Company Limited |
Nitrogen-containing heterocyclic compound
|
|
EP3313836B1
(en)
*
|
2015-06-26 |
2020-11-11 |
Takeda Pharmaceutical Company Limited |
2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
|
|
WO2017044693A1
(en)
|
2015-09-11 |
2017-03-16 |
Chase Pharmaceuticals Corporation |
Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
|
|
JP6787913B2
(ja)
|
2015-10-20 |
2020-11-18 |
武田薬品工業株式会社 |
複素環化合物
|
|
WO2017155050A1
(ja)
|
2016-03-11 |
2017-09-14 |
武田薬品工業株式会社 |
芳香環化合物
|
|
WO2018122845A1
(en)
|
2016-12-29 |
2018-07-05 |
Rvx Therapeutics Ltd. |
Methods and compositions for potentiating cns drugs and reducing their side effects
|